{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:21:02Z","timestamp":1791976862561,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004482","name":"Kuwait University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.nano.2025.102805","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:18:22Z","timestamp":1737544702000},"page":"102805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Exploiting novel placental homing peptides for targeted drug delivery in breast cancer"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-5290","authenticated-orcid":false,"given":"Abdulaziz A.","family":"Alobaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-3147","authenticated-orcid":false,"given":"Harmesh","family":"Aojula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-314X","authenticated-orcid":false,"given":"Richard A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-5202","authenticated-orcid":false,"given":"Lynda K.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.nano.2025.102805_bb0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nano.2025.102805_bb0010","article-title":"Study on knowledge of chemotherapy\u2019s adverse effects and their self-care ability to manage - the cancer survivors impact","volume":"11","author":"Arunachalam","year":"2021","journal-title":"Clin Epidemiol Glob Health"},{"issue":"5","key":"10.1016\/j.nano.2025.102805_bb0015","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/pharmaceutics14051113","article-title":"Functionalization of nanoparticulate drug delivery systems and its influence in cancer therapy","volume":"14","author":"Seidu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2025.102805_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.nano.2025.102805_bb0025","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1021\/acsanm.1c00779","article-title":"Recent advances in nanoparticle-based cancer treatment: a review","volume":"4","author":"Bajpai","year":"2021","journal-title":"ACS Appl Nano Mater"},{"issue":"1","key":"10.1016\/j.nano.2025.102805_bb0030","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1080\/10717544.2022.2120566","article-title":"Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer","volume":"29","author":"Wathoni","year":"2022","journal-title":"Drug Deliv"},{"issue":"22","key":"10.1016\/j.nano.2025.102805_bb0035","doi-asserted-by":"crossref","first-page":"14475","DOI":"10.3390\/ijms232214475","article-title":"Advances in aptamers-based applications in breast cancer: drug delivery, therapeutics, and diagnostics","volume":"23","author":"Gholikhani","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.nano.2025.102805_bb0040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","article-title":"Peptide-drug conjugate-based novel molecular drug delivery system in cancer","volume":"42","author":"Zhu","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.nano.2025.102805_bb0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1042\/bst0320397","article-title":"Vascular zip codes in angiogenesis and metastasis","volume":"32","author":"Ruoslahti","year":"2004","journal-title":"Biochem Soc Trans"},{"issue":"28","key":"10.1016\/j.nano.2025.102805_bb0050","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1002\/adma.201200454","article-title":"Peptides as targeting elements and tissue penetration devices for nanoparticles","volume":"24","author":"Ruoslahti","year":"2012","journal-title":"Adv Mater"},{"issue":"12","key":"10.1016\/j.nano.2025.102805_bb0055","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/mt.2013.191","article-title":"Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32","volume":"21","author":"Agemy","year":"2013","journal-title":"Mol Ther"},{"issue":"42","key":"10.1016\/j.nano.2025.102805_bb0060","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.1114518108","article-title":"Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma","volume":"108","author":"Agemy","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.nano.2025.102805_bb0065","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1021\/acsomega.8b01051","article-title":"Au-CGKRK nanoconjugates for combating cancer through T-cell-driven therapeutic RNA interference","volume":"3","author":"Gulla","year":"2018","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.nano.2025.102805_bb0070","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.nano.2025.102805_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600349","article-title":"Tumor-homing peptides as tools for targeted delivery of payloads to the placenta","volume":"2","author":"King","year":"2016","journal-title":"Sci Adv"},{"issue":"15","key":"10.1016\/j.nano.2025.102805_bb0080","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.7150\/thno.19678","article-title":"Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy","volume":"7","author":"Cureton","year":"2017","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.nano.2025.102805_bb0085","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3390\/pharmaceutics13111778","article-title":"Targeted delivery of epidermal growth factor to the human placenta to treat fetal growth restriction","volume":"13","author":"Renshall","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2025.102805_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.placenta.2021.03.003","article-title":"A crossroad between placental and tumor biology: what have we learnt?","volume":"116","author":"Lala","year":"2021","journal-title":"Placenta"},{"issue":"2","key":"10.1016\/j.nano.2025.102805_bb0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","article-title":"Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases","volume":"1151","author":"Haran","year":"1993","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"1","key":"10.1016\/j.nano.2025.102805_bb0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","article-title":"Colorimetric determination of phospholipids with ammonium ferrothiocyanate","volume":"104","author":"Stewart","year":"1980","journal-title":"Anal Biochem"},{"key":"10.1016\/j.nano.2025.102805_bb0105","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jcis.2024.02.103","article-title":"Translational use of homing peptides: tumor and placental targeting","volume":"662","author":"Alobaid","year":"2024","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.nano.2025.102805_bb0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/08982109009036010","article-title":"Preclinical and clinical experience with a doxorubicin-liposome preparation","volume":"1","author":"Gabizon","year":"1990","journal-title":"J Liposome Res"},{"issue":"1","key":"10.1016\/j.nano.2025.102805_bb0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bjc.6600344","article-title":"A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer","volume":"87","author":"O'Byrne","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nano.2025.102805_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-9776(01)80001-1","article-title":"Liposome technology and the development of Myocet\u2122 (liposomal doxorubicin citrate)","volume":"10","author":"Swenson","year":"2001","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.nano.2025.102805_bb0125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.nano.2025.102805_bb0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.biopha.2008.10.001","article-title":"A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors","volume":"63","author":"Zhang","year":"2009","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.nano.2025.102805_bb0135","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2025.102805_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2018.11.004","article-title":"Peptide-based targeted therapeutics: focus on cancer treatment","volume":"292","author":"Araste","year":"2018","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.nano.2025.102805_bb0145","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1073\/pnas.0915146107","article-title":"From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway","volume":"107","author":"Card\u00f3-Vila","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.nano.2025.102805_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jb\/mvm109","article-title":"Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumour diagnosis and therapy","volume":"142","author":"Qin","year":"2007","journal-title":"J Biochem"},{"issue":"2","key":"10.1016\/j.nano.2025.102805_bb0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/carcin\/bgh329","article-title":"Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion","volume":"26","author":"Zou","year":"2005","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.nano.2025.102805_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI44798","article-title":"Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma","volume":"121","author":"Staquicini","year":"2011","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.nano.2025.102805_bb0165","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm720","article-title":"A tumor-homing peptide with a targeting specificity related to lymphatic vessels","volume":"8","author":"Laakkonen","year":"2002","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.nano.2025.102805_bb0170","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1158\/0008-5472.CAN-07-6752","article-title":"Mitochondrial\/cell-surface protein p32\/gC1qR as a molecular target in tumor cells and tumor stroma","volume":"68","author":"Fogal","year":"2008","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.nano.2025.102805_bb0175","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1073\/pnas.1104540108","article-title":"Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice","volume":"108","author":"Hamzah","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.nano.2025.102805_bb0180","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nbt0697-542","article-title":"\u03b1v Integrins as receptors for tumor targeting by circulating ligands","volume":"15","author":"Pasqualini","year":"1997","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.nano.2025.102805_bb0185","first-page":"722","article-title":"Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis","volume":"60","author":"Pasqualini","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.nano.2025.102805_bb0190","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1172\/JCI3008","article-title":"Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display","volume":"102","author":"Rajotte","year":"1998","journal-title":"J Clin Invest"},{"issue":"5349","key":"10.1016\/j.nano.2025.102805_bb0195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.nano.2025.102805_bb0200","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/scbi.2000.0334","article-title":"Targeting tumor vasculature with homing peptides from phage display","volume":"10","author":"Ruoslahti","year":"2000","journal-title":"Semin Cancer Biol"},{"issue":"33","key":"10.1016\/j.nano.2025.102805_bb0205","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1038\/onc.2011.537","article-title":"Transtumoral targeting enabled by a novel neuropilin-binding peptide","volume":"31","author":"Roth","year":"2012","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.nano.2025.102805_bb0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.nano.2025.102805_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119926","article-title":"Manufacturing drug co-loaded liposomal formulations targeting breast cancer: influence of preparative method on liposomes characteristics and in vitro toxicity","volume":"590","author":"Gkionis","year":"2020","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.nano.2025.102805_bb0220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jsps.2015.02.014","article-title":"Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells","volume":"24","author":"Alyane","year":"2016","journal-title":"Saudi Pharm J"},{"issue":"3","key":"10.1016\/j.nano.2025.102805_bb0225","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/jps.24307","article-title":"Determination of key parameters for a mechanism-based model to predict doxorubicin release from actively loaded liposomes","volume":"104","author":"Csuhai","year":"2015","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.nano.2025.102805_bb0230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.37349\/etat.2020.00005","article-title":"The impact of tumour pH on cancer progression: strategies for clinical intervention","volume":"1","author":"Ward","year":"2020","journal-title":"Explor Target Antitumor Ther"},{"issue":"1","key":"10.1016\/j.nano.2025.102805_bb0235","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jconrel.2013.08.034","article-title":"Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro\/in vivo live cell imaging","volume":"172","author":"Seynhaeve","year":"2013","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.nano.2025.102805_bb0240","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cells10071717","article-title":"In vitro cell toxicity and intracellular uptake of doxorubicin exposed as a solution or liposomes: implications for treatment of hepatocellular carcinoma","volume":"10","author":"Kullenberg","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.nano.2025.102805_bb0245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12935-018-0625-9","article-title":"Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells","volume":"18","author":"Wen","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"5","key":"10.1016\/j.nano.2025.102805_bb0250","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bph.12202","article-title":"Increasing doxorubicin activity against breast cancer cells using PPAR\u03b3-ligands and by exploiting circadian rhythms","volume":"169","author":"Arif","year":"2013","journal-title":"Br J Pharmacol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963425000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963425000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T02:48:37Z","timestamp":1740624517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963425000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"alternative-id":["S1549963425000048"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2025.102805","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting novel placental homing peptides for targeted drug delivery in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2025.102805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102805"}}